Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Associated Therapies: -

Clinical Trials

Impact of Formulation on Ciprofloxacin Oral Absorption

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ciprofloxacin

First Posted Date: 2009-10-09

Last Posted Date: 2020-11-06

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 16

Registration Number: NCT00992329

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States

N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media

Phase 4

Withdrawn

Conditions: Otitis Media
Otorrhea

Interventions: Drug: Ciprodex
Drug: Ciprodex and 2% NAC

First Posted Date: 2009-08-11

Last Posted Date: 2019-12-03

Lead Sponsor: St. Paul's Hospital, Canada

Registration Number: NCT00956748

Locations: 🇨🇦
St. Paul's Hospital BC Rotary Hearing & Balance Centre, Vancouver, British Columbia, Canada

Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)

Phase 3

Terminated

Conditions: Elevated Prostate Specific Antigen

Interventions: Drug: Ciprofloxacin

First Posted Date: 2009-02-10

Last Posted Date: 2014-08-01

Lead Sponsor: University of Chicago

Target Recruit Count: 85

Registration Number: NCT00840294

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Longitudinal Study of the Human Intestinal Microbiome

Phase 1

Completed

Conditions: Dysbacteriosis

Interventions: Drug: Ciprofloxacin

First Posted Date: 2009-01-30

Last Posted Date: 2021-07-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00832286

Locations: 🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States

Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation

Phase 3

Completed

Conditions: Sepsis
Chronic Obstructive Pulmonary Disease
Antibiotics

Interventions: Drug: trimethoprim-sulfamethoxazole
Drug: ciprofloxacin

First Posted Date: 2008-11-14

Last Posted Date: 2020-02-24

Lead Sponsor: University of Monastir

Target Recruit Count: 170

Registration Number: NCT00791505

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

Phase 3

Completed

Conditions: Infectious Diseases

Interventions: Drug: Non-quinolone antibiotic
Drug: Ciprofloxacin

First Posted Date: 2008-09-29

Last Posted Date: 2015-07-31

Lead Sponsor: Bayer

Target Recruit Count: 1029

Registration Number: NCT00761462

Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients

Phase 4

Withdrawn

Conditions: Infections
Cirrhosis
Ascites

Interventions: Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2008-09-25

Last Posted Date: 2012-12-05

Lead Sponsor: Florencia Vargas-Vorackova

Registration Number: NCT00760032

Locations: 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, D.f., Mexico

Ciprofloxacin Multiple Dose for Adult Cholera

Phase 3

Completed

Conditions: Cholera

Interventions: Drug: Ciprofloxacin
Drug: Azithromycin

First Posted Date: 2008-08-26

Last Posted Date: 2011-07-12

Lead Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh

Target Recruit Count: 218

Registration Number: NCT00741052

Locations: 🇧🇩
ICDDR,B, Dhaka, Bangladesh

Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's

Phase 3

Completed

Conditions: Crohn's Disease With Perianal Fistulas

Interventions: Drug: adalimumab
Drug: ciprofloxacin

First Posted Date: 2008-08-18

Last Posted Date: 2012-04-17

Lead Sponsor: Foundation for Liver Research

Target Recruit Count: 76

Registration Number: NCT00736983

Locations: 🇳🇱
LUMC, Leiden, Netherlands
🇳🇱
St Antonius ziekenhuis, Nieuwegein, Netherlands
🇳🇱
UMC Radboud, Nijmegen, Netherlands

and more 10 locations

Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)

Phase 2

Completed

Conditions: Urinary Tract Infections

Interventions: Drug: Finafloxacin
Drug: Ciprofloxacin

First Posted Date: 2008-07-28

Last Posted Date: 2009-06-11

Lead Sponsor: MerLion Pharmaceuticals GmbH

Target Recruit Count: 36

Registration Number: NCT00722735

Locations: 🇸🇬
National University Hospital, Singapore, Singapore
🇩🇪
Medical practice, Dr. J. Hein (Principal Study Investigator), Marburg, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy